Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Enzastaurin - Denovo Biopharma

Drug Profile

Enzastaurin - Denovo Biopharma

Alternative Names: DB 102; Enzastaurin hydrochloride; Kinenza; LY-317615

Latest Information Update: 04 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Denovo Biopharma; Eli Lilly and Company
  • Class Antineoplastics; Indoles; Piperidines; Pyridines; Pyrrolidinones; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Protein kinase C beta inhibitors; Protein-serine-threonine kinase inhibitors; Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma; Diffuse large B cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Diffuse large B cell lymphoma
  • Discontinued Brain cancer; Breast cancer; Cancer; Colorectal cancer; Follicular lymphoma; Glioblastoma; Lung cancer; Lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Renal cancer; Solid tumours; Waldenstrom's macroglobulinaemia

Most Recent Events

  • 15 Oct 2019 US FDA approves IND application for Enzastaurin in Glioblastoma (Combination therapy, First-line therapy) for a phase IIb clinical trial (PO, Tablet)
  • 15 Oct 2019 Denovo Biopharma plans a phase IIb trial for Glioblastoma (Newly diagnosed) (Combination therapy, First-line therapy) in USA in June 2019 (PO, Tablet) (NCT03776071)
  • 26 Nov 2018 Pharmacodynamics data from preclinical studies in Diffuse large B cell lymphoma released by Denovo Biopharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top